Citadel Advisors
INMB icon

Citadel Advisors’s INmune Bio INMB Stock Holding History

Citadel Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1K Sell
12,500
-33,200
-73% -$47.3K ﹤0.01% 12719
2025
Q4 		$71.3K Sell
45,700
-154,900
-77% -$276K ﹤0.01% 11860
2025
Q3 		$415K Sell
200,600
-247,200
-55% -$566K ﹤0.01% 9572
2025
Q2 		$1.03M Buy
447,800
+433,000
+2,926% +$3.18M ﹤0.01% 7011
2025
Q1 		$116K Sell
14,800
-47,700
-76% -$379K ﹤0.01% 11257
2024
Q4 		$292K Buy
62,500
+33,200
+113% +$173K ﹤0.01% 9711
2024
Q3 		$158K Buy
29,300
+16,900
+136% +$120K ﹤0.01% 10500
2024
Q2 		$109K Sell
12,400
-9,000
-42% -$88.7K ﹤0.01% 10794
2024
Q1 		$251K Buy
21,400
+12,600
+143% +$152K ﹤0.01% 9852
2023
Q4 		$99.1K Sell
8,800
-1,300
-13% -$10.9K ﹤0.01% 10948
2023
Q3 		$69.1K Sell
10,100
-2,700
-21% -$22.4K ﹤0.01% 11337
2023
Q2 		$116K Sell
12,800
-3,200
-20% -$25.7K ﹤0.01% 10710
2023
Q1 		$103K Sell
16,000
-12,400
-44% -$99.9K ﹤0.01% 11215
2022
Q4 		$180K Sell
28,400
-500
-2% -$3.55K ﹤0.01% 10318
2022
Q3 		$179K Buy
28,900
+6,400
+28% +$56.2K ﹤0.01% 10514
2022
Q2 		$199K Sell
22,500
-6,400
-22% -$47.6K ﹤0.01% 10694
2022
Q1 		$243K Sell
28,900
-16,300
-36% -$146K ﹤0.01% 11071
2021
Q4 		$461K Buy
45,200
+7,200
+19% +$107K ﹤0.01% 9897
2021
Q3 		$738K Sell
38,000
-17,400
-31% -$336K ﹤0.01% 8921
2021
Q2 		$973K Buy
+55,400
New +$747K ﹤0.01% 8436

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's INMB Position: Q2 2025 in Review

Citadel Advisors sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 101,511 shares — an estimated $745K sold.

Citadel Advisors first reported a position in INMB in Q1 2019 and held it in 17 quarters. The position peaked at $1.02M in Q3 2021. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • Citadel Advisors reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 101,511 INmune Bio shares in Q2 2025, an estimated $745K.
  • Citadel Advisors first reported a position in INmune Bio in Q1 2019 and held it in 17 quarters.
  • Citadel Advisors's INmune Bio position peaked at $1.02M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.